{"ATC Code":["N - Nervous system","N01 - Anesthetics","N01A - Anesthetics, general","N01AB - Halogenated hydrocarbons","N01AB08","N01AB08","N01AB08 - Sevoflurane","QN - Nervous system","QN01 - Anesthetics","QN01A - Anesthetics, general","QN01AB - Halogenated hydrocarbons","QN01AB08 - Sevoflurane"],"Abbreviation":["sevo"],"Absorption, Distribution and Excretion":"Sevoflurane is rapidly absorbed into circulation through the lungs; however, solubility in the blood is low (blood/gas partition coefficient at 37°C ranges from 0.63 to 0.69). Therefore, a minimal amount of sevoflurane needs to be dissolved in blood in order to induce anesthesia.","Adverse Effects":"Neurotoxin - Acute solvent syndrome","Aliases":["1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane","Sevofluran","Ultane","Sevorane","Sevoflurano","Sojourn","MR6S4","sevoflo","Sevofluranum","Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-","Sevocalm","Petrem","MR-6S4","NSC-760367","Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether","CHEBI:9130","Dtxcid6026614","Ether, fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl-","fluoromethyl hexafluoroisopropyl ether","Sevospire","FlurovessTM","fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether","Sevoflurane Bostonbio","N01AB08","643-089-7","Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether","Mfcd00153189","1H,1H,3H-Perfluoro(3-methyl-2-oxabutane)","Sevofrane","1173021-96-9","Propane,1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-","Ncgc00167421-01","A1IPI","Bax 3084","Sevoflurane-d3,  Fluoromethyl  1,1,1,3,3,3-hexafluoro-2-propyl  ether-d3,  Fluoromethyl  2,2,2-trifluoro-1-(trifluoromethyl)ethyl  ether-d3","Brn 2041023","MR_6S4","Sevoflurane CRS","HSDB 8059","SevofluraneFluoromethyl","Fluoromethyl 2H-hexafluoroprop-2-yl ether","F0691","(Cf3)2choch2f","Schembl61918","GTPL7296","orb1305934","orb1940395","Chembl1200694","HMS3264N21","HMS5086J21","Pharmakon1600-01503680","Tox21_112425","NSC760367","SBB092545","Akos007930500","CCG-213707","DB01236","FS29164","NSC 760367","Ncgc00167421-02","Ncgc00167421-03","AC-15484","AS-13261","SY050207","Cas-28523-86-6","DB-047409","NS00014360","C07520","D00547","D78401","En300-123016","Sbi-0653442.0001","T22425","Ab01563174_01","F010315","Sr-01000944968","Sr-01000944968-1","Brd-k05638300-001-01-2","Z1269113624","2,2,2-trifluoro-1-(fluoromethoxy)-1-(trifluoromethyl)ethane"],"Associated Disorders and Diseases":"Solvents, acute toxic effect [Category: Acute Poisoning]","Biological Half-Life":"The terminal elimination half-life of sevoflurane from the peripheral fat compartment is approximately 20 hours.","Boiling Point":"58.1-58.2 °C at 751 mm Hg; 585.5 °C at 760 mm Hg","CAS":"28523-86-6","Chemical Classes":"Other Uses -\u003e Waste Anesthetic Gases","ChemicalClasses":["ether"],"Chirality":"achiral","Color/Form":"Liquid","DTXSID":"8046614","Density":"1505 at 25 °C/D g/cm\u003csup\u003e3\u003c/sup\u003e","Drug Classes":["Breast Feeding","Lactation","Anesthetics, Inhalation"],"Drug Indication":"Sevoflurane is used for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.","Drug Warnings":"Potassium hydroxide containing CO2 absorbents (e.g. BARALYME) are not recommended for use with sevoflurane, USP.","DurationOfAction":"","EliminationHalfLife":"15 – 23 hours","Erowid Experience Reports":[],"Esters":[],"European Community (EC) Number":"643-089-7","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":31,"Value":{"StringWithMarkup":[{"String":"38LVP0K73A"}]}},{"Name":"Active Moiety","ReferenceNumber":31,"Value":{"StringWithMarkup":[{"String":"SEVOFLURANE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":31,"Value":{"StringWithMarkup":[{"String":"Physiologic Effects [PE] - General Anesthesia"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":31,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - General Anesthetic"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":31,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-5206","Length":11,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Sevoflurane"},{"Extra":"CID-5206","Length":11,"Start":63,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/sevoflurane"}],"String":"Sevoflurane is a General Anesthetic. The physiologic effect of sevoflurane is by means of General Anesthesia."}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":42,"Value":{"StringWithMarkup":[{"String":"SEVOFLURANE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":42,"Value":{"StringWithMarkup":[{"String":"General Anesthetic [EPC]; General Anesthesia [PE]"}]}}],"Formating":[],"HMDB ID":"HMDB0015366","HeavyAtomCount":12,"Human Drugs":"Breast Feeding; Lactation; Anesthetics, Inhalation","IUPACName":"1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane","InChI":"InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2","InChIKey":"DFEYYRMXOJXZRJ-UHFFFAOYSA-N","Interactions":"As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. When used to supplement alfentanil-N2O anesthesia, sevoflurane and isoflurane equally potentiate neuromuscular block induced with pancuronium, vecuronium or atracurium. Therefore, during sevoflurane anesthesia, the dosage adjustments for these muscle relaxants are similar to those required with isoflurane. Potentiation of neuromuscular blocking agents requires equilibration of muscle with delivered partial pressure of sevoflurane. Reduced doses of neuromuscular blocking agents during induction of anesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate muscle relaxation.","MeSH Headers":[{"Id":"M0053801","Link":"https://id.nlm.nih.gov/mesh/M0053801.html","Name":"Sevoflurane","Ref":71},{"Id":"M000639417","Link":"https://id.nlm.nih.gov/mesh/M000639417.html","Name":"Sevorane","Ref":73},{"Id":"M0397747","Link":"https://id.nlm.nih.gov/mesh/M0397747.html","Name":"Ultane","Ref":74},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":75},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":100},{"Id":"M0017012","Link":"https://id.nlm.nih.gov/mesh/M0017012.html","Name":"Platelet Aggregation Inhibitors","Ref":101},{"Id":"M0027998","Link":"https://id.nlm.nih.gov/mesh/M0027998.html","Name":"Anesthetics, Inhalation","Ref":102}],"MeSH Pharmacological Classification":[{"Id":"M0017012","Link":"https://id.nlm.nih.gov/mesh/M0017012.html","Name":"Platelet Aggregation Inhibitor","Ref":101},{"Id":"M0027998","Link":"https://id.nlm.nih.gov/mesh/M0027998.html","Name":"Anesthetics, Inhalation","Ref":102}],"Mechanism of Action":"The precise mechanism of action of sevoflurane has not been fully elucidated. Like other halogenated inhalational anesthetics, sevoflurane induces anesthesia by binding to ligand-gated ion channels and blocking CNS neurotransmission. It has been suggested that inhaled anesthetics enhance inhibitory postsynaptic channel activity by binding GABA\u003csub\u003eA\u003c/sub\u003e and glycine receptors, and inhibit excitatory synaptic channel activity by binding nicotinic acetylcholine, serotonin, and glutamate receptors. Sevoflurane has an effect on several ionic currents, including the hyperpolarisation-activated cation current (I\u003csub\u003ef\u003c/sub\u003e), the T-type and L-type Ca\u003csup\u003e2+\u003c/sup\u003e currents (I\u003csub\u003eCa, T\u003c/sub\u003e and I\u003csub\u003eCa, L\u003c/sub\u003e), the slowly activating delayed rectifier K\u003csup\u003e+\u003c/sup\u003e currents (I\u003csub\u003eKs\u003c/sub\u003e), and the Na\u003csup\u003e+\u003c/sup\u003e/Ca\u003csup\u003e2+\u003c/sup\u003e exchange current (I\u003csub\u003eNCX\u003c/sub\u003e). This ability to modulate ion channel activity can also regulate cardiac excitability and contractility.","Melting Point":"\u003c 25 °C","Metabolism/Metabolites":"Sevoflurane is metabolized to hexafluoroisopropanol by cytochrome P450 2E1 in a reaction that promotes the release of inorganic fluoride and carbon dioxide. Hexafluoroisopropanol is rapidly conjugated with glucuronic acid and eliminated in urine. _In vivo_ metabolism studies suggest that approximately 5% of the sevoflurane dose may be metabolized. In most cases, inorganic fluoride reaches its highest concentration within 2 hours of the end of sevoflurane anesthesia, and returns to baseline levels within 48 hours. Sevoflurane metabolism may be induced by chronic exposure to isoniazid and ethanol, and it has been shown that barbiturates do not affect it.","MolecularFormula":"C\u003csub\u003e4\u003c/sub\u003eH\u003csub\u003e3\u003c/sub\u003eF\u003csub\u003e7\u003c/sub\u003eO","MolecularWeight":"200.05 g/mol","Pharmacodynamics":"Sevoflurane induces muscle relaxation and reduces sensitivity by altering tissue excitability with a fast onset of action. It does so by decreasing the extent of gap junction-mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. Compared to [halothane] and [isoflurane], sevoflurane has a shorter emergence time, as well as a shorter time to first analgesia. To reach an equilibrium between alveolar and arterial partial pressure, only a minimal amount of sevoflurane needs to be dissolved in blood.   The use of sevoflurane can increase the risk of renal injury, respiratory depression, and QT prolongation. Also, it can lead to malignant hyperthermia, perioperative hyperkalemia, and pediatric neurotoxicity. Episodes of severe bradycardia and cardiac arrest have been reported in pediatric patients with Down Syndrome given sevoflurane. Sevoflurane anesthesia may impair the performance of activities requiring mental alertness, such as driving or operating machinery.","Physical Description":"A clear, nonflammable colorless liquid with a non-irritating odor; [ACGIH TLVs and BEIs]","PubChemId":5206,"PubChemTitle":"Sevoflurane","Record Description":["LiverTox|CNS|Anesthetic|Halogenated, volatile"],"Records":{"UNII":{"Impurities":["1,1,1,3,3-pentafluoroisopropenyl fluoromethyl ether","1,1,1,3,3,3-hexafluoro-2-methoxy-propane","1,1,1,3,3,3-hexafluoroisopropanol"]}},"Reddit Experience Reports":[],"RefChem":"57601","RefCount":4,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Sevoflurane","Name":"Sevoflurane","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q419394","Name":"Sevoflurane","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB01236","Name":"Sevoflurane","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5206","Name":"Sevoflurane","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=28523-86-6","Name":"Sevoflurane","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015366","Name":"Sevoflurane","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07520","Name":"Sevoflurane","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/38LVP0K73A","Name":"Sevoflurane","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID8046614","Name":"Sevoflurane","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5206, Sevoflurane. Accessed August 24, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5206\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5206\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Sevoflurane. UNII: 38LVP0K73A. Global Substance Registration System. Accessed August 24, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/38LVP0K73A\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/38LVP0K73A\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed August 24, 2026. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"C(OC(C(F)(F)F)C(F)(F)F)F","SaltData":[],"Salts":[],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Brazil","ref":["3"],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"Very slightly soluble","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 69.986 57.419\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#90e050\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".8\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h70v58H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m54.791 33.54-9.59 5.537M37.984 39.077l-9.59-5.537M28.394 33.54l-13.198 7.62M15.196 41.16l-6.28-10.876M15.196 41.16 4.698 47.221M15.196 41.16l5.382 9.323M28.394 33.54V18.3M28.394 18.3h12.202M28.394 18.3V6.247M28.394 18.3H15.99M54.791 33.54l10.374 5.99\" class=\"bond\"/\u003e\u003cpath fill=\"#ff0d0d\" stroke=\"none\" d=\"M41.595 39.115q-.738 0-1.172.554-.429.548-.429 1.494 0 .947.429 1.495.434.547 1.172.547.739 0 1.167-.547.429-.548.429-1.495 0-.946-.429-1.494-.428-.554-1.167-.554m0-.547q1.054 0 1.679.708.631.703.631 1.887 0 1.179-.631 1.887-.625.703-1.679.703-1.053 0-1.684-.703-.631-.702-.631-1.887 0-1.184.631-1.887.631-.708 1.684-.708\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M6.138 25.462h2.876v.571H6.817v1.471h1.982v.571H6.817v2.387h-.679zM.56 46.28h2.875v.572H1.239v1.47h1.982v.571H1.239v2.388H.56zM21.378 51.858h2.876v.572h-2.197v1.47h1.982v.572h-1.982v2.387h-.679zM42.196 15.8h2.876v.571h-2.197v1.471h1.983v.571h-1.983v2.388h-.679zM26.956.56h2.876v.572h-2.197v1.47h1.983v.571h-1.983v2.388h-.679zM11.716 15.8h2.876v.572h-2.197v1.47h1.983v.571h-1.983v2.388h-.679zM66.551 38.66h2.875v.571H67.23v1.471h1.982v.571H67.23v2.388h-.679z\" class=\"atom\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m45.201 39.077 4.795-2.769M37.984 39.077l-4.795-2.769\" class=\"hi\"/\u003e\u003cpath stroke=\"#90e050\" d=\"m8.916 30.284 3.14 5.438M4.698 47.221l5.249-3.03M20.578 50.483l-2.691-4.661M40.596 18.3h-6.101M28.394 6.247v6.027M15.99 18.3h6.202M65.165 39.53l-5.187-2.995\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Sevoflurane is an inhalational anesthetic agent for use in induction and maintenance of general anesthesia. Minimum alveolar concentration (MAC) of sevoflurane in oxygen for a 40-year-old adult is 2.1%. The MAC of sevoflurane decreases with age. /Included in US product label/","Title":"Sevoflurane","Toxicity Data":"LD50: 10.8 g/kg (Rat) (A308)\nLC50: 49881 ppm/hr (Inhalation, Rat) (A308)","Treatment":"In the event of overdosage, or what may appear to be overdosage, the following action should be taken: discontinue administration of sevoflurane, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function. (L1712)","UNII":"38LVP0K73A","Wikidata":"Q419394","Wikipedia":"Sevoflurane","XLogP":2.8}